ABCL · AbCellera Biologics Inc
United States · RS rating 93 · As of 2026-11-03
| Price | 12.18 USD |
|---|---|
| 1-day change | +9.5% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 33 / 97 / 95 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 50 / 66 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -28.6% |
| Sales growth Q/Q | +400.9% |
| Distance from 52-week high | +17.8% |
| Market cap (USD) | $1.2B |